Dr. Shroff on Unmet Needs in Advanced Biliary Tract Cancer
Rachna T. Shroff, MD, MS, discusses unmet needs in advanced biliary tract cancer.
Dr. Shroff on the Importance of Targeted Therapy in Advanced Biliary Tract Cancer
Rachna T. Shroff, MD, discusses the importance of targeted therapy in advanced biliary tract cancer.
Optimizing Precision Medicine in HCC
Takeaways from a discussion on treatment advances in hepatocellular carcinoma.
Biomarkers to Guide HCC Treatment Decisions
Professionals who treat patients with hepatocellular carcinoma comment on the need for more research and biomarkers to fuel treatment decisions.
Second-Line Treatment Approaches for Advanced HCC
An overview of the second-line treatment landscape for patients with advanced hepatocellular carcinoma and considerations regarding the sequencing of novel therapies.
The COSMIC-312 Study in Advanced HCC
Thoughts regarding the COSMIC-312 study of cabozantinib plus atezolizumab as frontline therapy for advanced hepatocellular carcinoma.
HCC: IO in Liver Transplant Recipients
A debate regarding the appropriateness of immunotherapy following liver transplantation in patients with hepatocellular carcinoma.
The LEGACY Study in HCC
Implications on treatment practices of the LEGACY study of Y-90 glass microspheres in patients with unresectable solitary hepatocellular carcinoma.
Selecting First-Line Therapy for Advanced HCC
An overview of factors that deem patients appropriate for atezolizumab/bevacizumab vs lenvatinib or sorafenib as frontline therapy for advanced hepatocellular carcinoma.
Frontline IO for Advanced HCC
Considerations regarding the use of nivolumab as frontline treatment for advanced hepatocellular carcinoma.
Systemic Treatment Advances for Advanced HCC
Exciting developments using novel therapies as systemic treatment for advanced hepatocellular carcinoma.
Scoring/Classifying Patients With Advanced HCC
Best practices using available scoring systems to evaluate and treat patients with advanced hepatocellular carcinoma.
Adjuvant Treatment Advances in Operable HCC
Perspectives regarding treatment advances using adjuvant approaches that include immunotherapy to treat early-stage hepatocellular carcinoma.
Hepatic Arterial Infusion Chemotherapy for HCC
Reactions to recent clinical abstracts that support the use of hepatic arterial infusions for chemotherapy delivery in hepatocellular carcinoma.
Neoadjuvant Therapy to Downstage HCC
Reactions to treatment gaps in the neoadjuvant space for hepatocellular carcinoma and implications for incorporating data supporting newer, novel systemic therapies for appropriate patients.
Advances in Locoregional Therapy for Early Stage HCC
University of Arizona’s Rachna Shroff, MD, describes the role of systemic therapy with locoregional treatment for early stage hepatocellular carcinoma and highlights treatment strategies of interest that remain under investigation.
Current Role of Locoregional Therapy for Early Stage HCC
Edward Kim, MD, of Mount Sinai Health System describes where advances in locoregional therapy for early-stage hepatocellular carcinoma fit into the therapeutic landscape.
Diagnosing Early-Stage HCC via Biopsy
A debate regarding the current role of biopsy to confirm a diagnosis of early-stage hepatocellular carcinoma.
Diagnostic Testing for Early Stage HCC
The rationale for diagnostic imaging to evaluate and diagnose early stage hepatocellular carcinoma.
Screening for Early Stage HCC
A brief overview of criteria and tools used to assess, and risk stratify patients with early stage hepatocellular carcinoma.
Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis
Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment
First-line Toripalimab Plus Sorafenib Elicits Responses in Unresectable Hepatocellular Carcinoma
Data for Luspatercept Highlight Evolving Treatment Landscape in Lower-Risk MDS
2 Clarke Drive Cranbury, NJ 08512